Skip to main content

Search for new therapeutic agents against complicated obesity by reprofiling existing drugs

Objectif

Obesity is one of the most serious and fast-growing health problem in the European Union, and a leading cause of diabetes. The main barrier for approval of an anti-obesity drug is the safety requirements. We propose to overcome this barrier by discovering phenotypes and biomarkers that identify subsets of patients with safe and efficacious responses to drugs, and by identifying new indications of existing drugs with proven safety profiles. To be approved, anti-obesity drugs need to show a decrease in abdominal fat. We focus on approaches targeting directly abdominal fat cells. In the last years only the cannabinoid CB1 receptor antagonist Rimonabant has been approved as a therapeutic agent to combat complicated obesity. Research performed with this drug has clearly revealed a role for the endogenous cannabinoid system in controlling energy homeostasis. However, its utility is limited to a restricted set of patients. A new phenotype and/or biomarker may identify responsive patients with good safety profiles. This proposal aims to discover novel or improved treatments in the shortest possible timeframe through three synergistic Specific Aims: 1) Clinical phenotyping of obese patients to identify those that would benefit from existing therapies such as Rimonabant. 2) Discover biomarkers for subsets of obese patients that may correlate with therapeutical outcomes. These biomarkers will be discovered by a novel approach called Combinatorial Cytomic Biomarkers developed by OrphaMed, applied to cells from two physiologically interlinked sources: blood and abdominal-fat samples, extracted from the above phenotyped patients. 3) Identify new indications of existing drugs, alone or in combination, with potential anti-obesity efficacy by lowering the fat content and the glucose uptake of abdominal fat cells, which would be expected to improve carbohydrate/lipid metabolism and lower body weight, extracted from the above phenotyped patients. This will be accomplished by screening approximately 2.000 known drugs against these fat cells using the novel technology platform “ExviTech” from OrphaMed. Candidates would be evaluated in animal models of obesity.

Appel à propositions

FP7-HEALTH-2007-B
Voir d’autres projets de cet appel

Coordinateur

FUNDACION PUBLICA ANDALUZA PARA LA INVESTIGACION DE MALAGA EN BIOMEDICINA Y SALUD
Adresse
Calle Severo Ochoa 35, Parque Tecnologico De Andalucia
29580 Malaga
Espagne

Voir sur la carte

Type d’activité
Research Organisations
Contact administratif
Fernando Rodriguez De Fonseca (Dr.)
Contribution de l’UE
€ 594 005

Participants (6)

VIVIA BIOTECH S.L.
Espagne
Contribution de l’UE
€ 2 723 786
Adresse
C Santiago Grisolia 2 Oficina 205
28760 Tres Cantos Madrid

Voir sur la carte

Type d’activité
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Contact administratif
Olivia De La Lama Noriega (Ms.)
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
France
Contribution de l’UE
€ 505 440
Adresse
Rue De Tolbiac 101
75654 Paris

Voir sur la carte

Type d’activité
Research Organisations
Contact administratif
Giovanni Marsicano (Dr.)
JOHANNES GUTENBERG-UNIVERSITAT MAINZ
Allemagne
Adresse
Saarstrasse 21
55122 Mainz

Voir sur la carte

Type d’activité
Higher or Secondary Education Establishments
Contact administratif
Beat Lutz (Prof.)
ALMA MATER STUDIORUM - UNIVERSITA DI BOLOGNA
Italie
Contribution de l’UE
€ 508 860
Adresse
Via Zamboni 33
40126 Bologna

Voir sur la carte

Type d’activité
Higher or Secondary Education Establishments
Contact administratif
Alessandra Malavolta (Dr.)
UNIVERSIDAD DE SANTIAGO DE COMPOSTELA
Espagne
Contribution de l’UE
€ 505 919
Adresse
Colexio De San Xerome Praza Do Obradoiro S/n
15782 Santiago De Compostela

Voir sur la carte

Type d’activité
Higher or Secondary Education Establishments
Contact administratif
Fernando Sedano Arnaez (Dr.)
UNIVERSITAETSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITAET MAINZ
Allemagne
Contribution de l’UE
€ 561 402
Adresse
Langenbeckstrasse 1
55131 Mainz

Voir sur la carte

Type d’activité
Higher or Secondary Education Establishments
Contact administratif
Uta Veith (Dr.)